Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.58 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | PRF1 | P14222 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910088 | 0.87 | MET (0.56) | METTRPC5CHRM4PRF1 | |
| SCHEMBL9924281 | 0.85 | MET (0.60) | METCHRM4 | |
| SCHEMBL2696925 | 0.84 | MET (0.59) | METCHRM4 | |
| SCHEMBL2695986 | 0.79 | MET (0.51) | METCHRM4PRF1KDM4ESMN1; SMN2 | |
| SCHEMBL2699324 | 0.70 | TRPC5 (0.45) | METTRPC5KDM4E | |
| SCHEMBL2695820 | 0.69 | MET (0.54) | METTRPC5KDM4ESMN1; SMN2 | |
| SCHEMBL2698083 | 0.69 | MET (0.53) | METTRPC5KDM4ESMN1; SMN2 | |
| SCHEMBL2695905 | 0.68 | TRPC5 (0.41) | METTRPC5KDM4ESMN1; SMN2 | |
| SCHEMBL2696398 | 0.67 | MET (0.49) | METTRPC5 | |
| SCHEMBL2695540 | 0.67 | KDM4E (0.47) | METTRPC5KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3093289-A1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR | Amgen, Inc (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2081931-B1 | [1,2,4]Triazolo[4,3-a]pyridine derivatives useful as inhibitors of the hepatocyte growth factor receptor | AMGEN INC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9066954-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8524900-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2578583-A1 | Fused heterocyclic derivatives and methods of use | Amgen Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8217177-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8212041-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8198448-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885TRPC5 4458/4885CHRM4 4246/4885 |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885TRPC5 4458/4885CHRM4 4246/4885 |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885TRPC5 4458/4885CHRM4 4246/4885 |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885TRPC5 4458/4885CHRM4 4246/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | MET 3/4885TRPC5 4458/4885CHRM4 4246/4885 |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885TRPC5 4458/4885CHRM4 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.